Patient documentary - From diagnosis to everyday living
Patient documentary - From diagnosis to everyday living
Search
Jardiance®
Treatment of adults with type 2 diabetes mellitus as an adjunct to diet and exercise.
Bernard Mental Health Impact
Harold and Friends learn about how living with multiple health conditions can impact mental health
Boehringer Ingelheim announces Reach Africa Access Healthcare programs outcomes
Boehringer Ingelheim, announces “In Reach Africa” Access to Healthcare programs outcomes
Connect with your heart
If you know someone who has #type2diabetes, they are twice as likely to develop heart failure than those without.
Glyxambi®
Treatment of type 2 diabetes mellitus to improve glycaemic control in adults when treatment with both empagliflozin and linagliptin is appropriate (US).
Boehringer Ingelheim Empowers 380 Regional Experts with Latest Insights in Cardio-Renal-Metabolic Care
Boehringer Ingelheim hosted the ‘CRM 360 standalone meeting’, ‘IMETA CRM Discussions for EXperts (MEDEX)’, to discuss the latest advances in the management of cardio-renal-metabolic conditions
Trajenta®
Treatment of type 2 diabetes mellitus to improve glycaemic control in adults, used in monotherapy (if metformin is not tolerated or contraindicated) or in combination therapy.
Obesity
Obesity
Jentadueto®
Treatment of type 2 diabetes mellitus to improve glycaemic control in adults when treatment with metformin does not lead to sufficient control or when patients are treated with trajenta® (linagliptin) and metformin.
Synjardy®
Treatment of type 2 diabetes mellitus to improve glycaemic control in adults when treatment with metformin does not lead to sufficient control or when patients are treated with jardiance® (empagliflozin) and metformin.
A Unique Bond: a brotherhood like no other
After being diagnosed with diabetes, Eric’s unique bonds with Peetey and Jake meant they could run miles across the Idaho wilderness.
Cardiometabolic Research
Read about our patient-centric approach to cardiometabolic disease research.
NASH
NASH
Collaboration to fight NCDs
70 percent of global deaths are attributable to NCDs and severely impacting on people in low- and middle-income countries. Help is desperately needed.
Fighting Negative KRAS Feedback
Boehringer Ingelheim scientists are directly targeting KRAS, blocking feedback and ultimately getting ahead of resistance by investigating pan-KRAS approaches. Article from Marco Hofmann
Heart Failure
Heart Failure
Understanding heart failure
Heart failure is a complicated clinical condition which affects more than 60 million people worldwide. Find out more about the condition here.
Bridging the gap in Generalized Pustular Psoriasis (GPP)
Emmanuelle Clerisme-Beaty, Head of Clinical Development and Medical Affairs, Dermatology, discusses recently published insights from GPP patients.
Eyes on Retina. The Podcast.
In this podcast series, we hear from a range of retinal experts involved in the care of people living with retinal diseases.
IPF treatment discussions
Listen to Steve Jones (a person living wih IPF) and Dr. Marlies Wijsenbeek (a leading pulmonologist) discuss the importance of treatment discussions in IPF
Retinal Health Research
Read about our holistic approach to retinal health research.
Non-Small Cell Lung Cancer
NSCLC is the most common form of lung cancer. EGFR M+ NSCLC is a subtype of lung cancer and is identified via a mutation test. Find out more here.
Cardiometabolic Diseases
We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in CardioMetabolic diseases.
Boehringer Ingelheim Convenes Educational Meetings to Empower Over 300 Regional Experts with Latest Heart Failure Advances
• Boehringer Ingelheim hosted ‘Heart Talks’and ‘MEDEX’ to discuss latest updates in heart failure management and help improve patient outcomes across India, the Middle East and Africa